A patient developed lithium toxicity after switching from semaglutide to tirzepatide, highlighting dangerous drug interactions with GLP-1 medications.
Toxicity from GLP-1 switchStable lithium levels became toxic when semaglutide was changed to tirzepatide
What the researchers found
Switching from semaglutide to tirzepatide precipitated lithium toxicity in a patient with schizoaffective disorder, demonstrating clinically significant pharmacokinetic interactions with GLP-1 RAs.
Why it matters
Millions take GLP-1 drugs alongside other medications. This case shows that switching between GLP-1 agents is not pharmacokinetically neutral and requires monitoring.
How the study worked
Single case report of lithium toxicity temporally associated with a switch from semaglutide to tirzepatide.
What this study cannot tell us
Single case report — individual factors may have contributed. The exact pharmacokinetic mechanism is not fully characterized.
How to read the evidence
Single case report — lowest evidence level but critically important for drug safety awareness.
When this study was published
Published in 2026; relevant as GLP-1 drug switching becomes more common.
The bigger picture
As GLP-1 drug switching becomes more common due to insurance, supply, or preference changes, drug interaction monitoring must become standard practice.
Questions still open
- Should lithium levels be routinely monitored when changing GLP-1 medications?
- Which other narrow-therapeutic-index drugs are affected by GLP-1 switching?
Common questions
Can GLP-1 drugs interact with other medications?
What should I tell my doctor if I switch GLP-1 drugs?
Read the original research
Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management.
The mental health clinician, 16(1), 34-38
Citation
Burson, Jesse R; Leung, Jonathan G. (2026). Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management.. The mental health clinician, 16(1), 34-38. https://doi.org/10.9740/mhc.2026.02.034